FRC
FRC Logo
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us

Resources

  • Videos
  • Research Reports
  • FAQ

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Research
Get Access
Sign In
Kezar Life Sciences, Inc. Stock AnalysisComprehensive stock analysis for Kezar Life Sciences, Inc. (KZR) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisKZR
KZR
Kezar Life Sciences, Inc.
  • Company Overview
  • FRC Research
  • Financial Data
  • Peer Comparison
  • Ownership & News
KZR
Home🔹Stocks🔹Kezar Life Sciences, Inc.

Kezar Life Sciences, Inc.

KZR•NASDAQ

Kezar Life Sciences, Inc.

KZR•NASDAQ
Market cap
$53.86M
Sentiment

Your view on KZR

Mkt Cap
$53.86M
Sentiment
Your view
KZR
Kezar Life Sciences, Inc.
  • Company Overview
  • FRC Research
  • Financial Data
  • Peer Comparison
  • Ownership & News
KZR
Company Overview

Overview

What the company does, where it operates, and who runs it.

About Kezar Life Sciences, Inc.

Industry
Biotechnology
Sector
Healthcare
CEO
Christopher J. Kirk
Headquarters
4000 Shoreline Court, South San Francisco, CA, US
Industry
Biotechnology
Sector
Healthcare
CEO
Christopher J. Kirk
Headquarters
4000 Shoreline Court, South San Francisco, CA, US
Description

Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is KZR-616, a selective immunoproteasome inhibitor that is in Phase 2 clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; and Phase 1b clinical trials in systemic lupus erythematosus and lupus nephritis. Its preclinical products include KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of KZR-261; and KZR-TBD for the treatment of oncology and immunology. The company was incorporated in 2015 and is based in South San Francisco, California.

Infographics

Visual summary of the business at a glance.

FRC Research

Media

Videos and interviews covering the company.

Financial Data

Stock Data

Price chart, volume, and trading data.

Fair Value

What FRC thinks the stock is worth vs. the current price.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

Dividend Analysis

Yield, payout ratio, and dividend coverage metrics.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

Financial Statements

Income statement, balance sheet, and cash flow statements.

Peer Comparison

Comparables

List of peer companies in the same industry.

Ownership & News

Institutional Ownership

Which funds and firms own the stock.

Insider Trading

Recent buying and selling by company executives.

Senate Trading

U.S. Senator disclosures filed under the STOCK Act.

News

Latest headlines and market coverage.

News

Latest Market News